Cornerstone Pharmaceutical

CStone Pharmaceuticals is a leading biopharmaceutical company in China focused on developing and commercializing innovative immuno-oncology and precision medicines to address unmet medical needs in oncology. The company has built a robust pipeline of over 15 oncology drug candidates, including several late-stage assets and multiple approved products. Key commercial assets include sugemalimab (a PD-L1 antibody), nofazinlimab (a PD-1 antibody), and several licensed-in precision medicines such as avapritinib and ivosidenib. CStone has established strategic partnerships with global pharmaceutical leaders like Pfizer and Blueprint Medicines to accelerate the development and commercialization of its portfolio. The company is headquartered in Suzhou, China, and is publicly traded on the Hong Kong Stock Exchange.